result of the deletions resulting from these rearrangements, clonal B cells or plasma cells will have unique patterns of deletion in the V H yD H yJ H region of the IgH loci. At later stages of B-cell development, IgH switch recombination can reposition the V H D H J H sequence near downstream constant regions (C H ). As a result, clonal B cells or plasma cells that have undergone IgH switch recombination also will have clonal patterns of deletion in the C H region of the IgH locus. Often the B-cell specific deletions described above are large enough to be detected as a homozygous copy number loss using comparative genomic hybridization or single-nucleotide polymorphism arrays. Therefore, copy number changes in the IgH locus have the potential to provide a measure of contamination of clonal B or plasma cells with other cells.
Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option for most adult patients with high-risk or relapsed acute myeloid leukemia (AML), with conventional conditioning being the standard-of-care consolidation therapy for patients with cytogenetically defined high-risk AML. 1 Unfortunately, only 40-50% of patients in this category achieve a first complete remission (CR). The remaining patients experience refractory disease or early death that also applies for patients with relapsed AML. Novel strategies that allow earlier allogeneic HCT could lead to a higher number of patients being sufficiently transplanted before refractory disease develops and, most importantly, before cumulative toxicities occur during induction and salvage therapy and render patients ineligible for allogeneic HCT. In addition, reduced-intensity conditioning (RIC) regimens can be administered in older patients with AML or those who present with a reduced performance status and in whom intensive conditioning procedures may be harmful and may facilitate the initiation of conditioning therapy as early as 5-10 days after the end of cytarabine-containing induction or salvage chemotherapy. [1] [2] [3] [4] Different forms of RIC regimens have been administered showing feasibility, durable remission and acceptable transplantrelated mortality.
3,5-9 Our intent-to-treat approach included allogeneic HCT during chemotherapy-induced aplasia after a maximal reduction of 'leukemia burden'. We analyzed all sequential patients undergoing allogeneic HCT during chemotherapy-induced aplasia for primary refractory AML, high-risk or relapsed AML at our institution since the introduction of this novel concept.
We performed a retrospective, single-center cohort analysis in a study population comprising 95 patients with a median age of 52 years (range, 17-71 years). Inclusion criteria was AML diagnosis according to the current WHO criteria and first allogeneic HCT during chemotherapy-induced aplasia between December 1998 and March 2009. Patients with cord-blood, haploidentical and second allogeneic HCT were excluded from the analysis. The study was approved by the ethics committee of the Technical University Letters to the Editor Dresden and the institutional review board. Allogeneic HCT during chemotherapy-induced aplasia was performed in 65 patients with high-risk AML and in 30 patients with relapsed AML. High-risk AML was defined on the basis of cytogenetics, FLT3-ITD mutation status and blast clearance in the bone marrow on day 15 after initiation of induction chemotherapy as described recently. 10 Therefore, of the 65 high-risk patients, 47 were primary refractory to induction chemotherapy and 18 patients were transplanted during chemotherapy-induced aplasia due to high-risk genetic features. Previously untreated patients were not included in this analysis. A total of 44 patients in this analysis were treated in the prospective, randomized, multicenter AML2003 trial of the Study Alliance Leukemia (SAL). Allogeneic HCT was part of the intensified therapy arm of the AML2003 trial as described recently. 11 Of the 44 patients treated within the AML2003 trial, 21 patients were transplanted during chemotherapy-induced aplasia because of primary refractory disease, 12 patients were transplanted because of relapsed AML, whereas the remaining 11 patients were a priori included because of the underlying high-risk genetic features. The protocol was in accordance with the Helsinki Declaration and registered with the NCT numbers 00180102. Written informed consent was obtained from all patients.
Bone marrow and peripheral blood samples were obtained at diagnosis, and mutational analysis for NPM1 exon 12 and FLT3-ITD were performed as previously reported. 12 Comorbidities were grouped according to the hematopoietic cell transplantationspecific comorbidity index (HCT-CI). 13 Of the 95 patients reported here, 26 were described in a previous study reporting the outcome of patients with newly diagnosed high-risk AML undergoing allogeneic HCT during chemotherapy-induced aplasia, whereas the current study analysis also includes patients with relapsed AML.
2 DNA-based HLA typing of donors and recipients was performed using high resolution (four digits) for HLA-A and -B, DRB1 and DQB1 as well as intermediate resolution (two digits) for HLA-C. Twenty-eight recipient-unrelated donor pairs were mismatched for a one-locus (allele or antigen), 29 were transplanted from HLA-identical siblings, and 38 recipients had HLA-matched unrelated donors. Cytomegalovirus seropositivity in either donor or recipient was apparent in 75 patients. G-CSFmobilized peripheral blood stem cells (PBSC) were used as graft source in 91 patients. The majority of patients (n ¼ 71, 75%) received conditioning therapy based on a combination of fludarabine (30 mg/m 2 from day À 6 to day À 2) and melphalan (150 mg/m 2 on day À 2). Six patients received fludarabine and busulfan (3.3 mg/kg on days À 6 and À 5), 16 patients received fludarabine and fractionated TBI (2 Â 200 cGy on days À 3 and À 2, cumulative dose 800 cGy), whereas two patients received cyclophosphamide (40 mg/kg on days À 3 and À 2) and TBI (8 Gy). Antithymocyte globulin (ATG, 10 mg/kg/day, on days À 5 to À 2, total dose 40 mg/kg; Fresenius, Bad Homburg, Germany) was administered in case of an unrelated (n ¼ 38) or one-allele HLA-mismatched (n ¼ 28) donor transplantation. PBSC grafts were infused on day 0 without further manipulation. A median of 6.6 Â 10 6 /kg CD34 þ cells (range, 1.29-12) were transplanted. Information about the statistical analyses is depicted in the supplement.
Detailed patient characteristics are shown in Table 1 . Allogeneic HCT during aplasia was performed in 65 patients because of highrisk characteristics defined on the basis of adverse-risk cytogenetics (n ¼ 49) and/or inadequate blast clearance after induction chemotherapy (n ¼ 47), and/or FLT3-ITD mutations (n ¼ 13) and in 30 patients because of relapsed AML with a median follow-up for all patients of 3.6 years (range, 0.2-10.6 years). HLA-typing took a median of 2 days (range 1-8 days) from the date of entry in the HLA laboratory until the final report, respectively. A total of 52 patients underwent one cycle of induction/salvage chemotherapy and 43 received two cycles of induction/salvage chemotherapy with subsequent chemotherapy-induced aplasia during which Abbreviations: AML, acute myeloid leukemia; Ara-C, cytarabine; FLT3, fms -like tyrosine kinase 3; HCT, hematopoietic stem cell transplantation; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; ITD, internal tandem duplication; MMF, mycophenolate mofetil; NPM1, nucleophosmin 1; PBSC, peripheral blood stem cells; UD, unrelated donor. Letters to the Editor allogeneic HCT was performed. Information on engraftment, graftversus-host disease (GvHD) and toxicities are shown in supplementary Table 1 . A cytomorphological CR was documented in 82 patients (86%) after allogeneic HCT. Seven patients failed to achieve a CR because of progressive AML or because they died of complications before a CR could be documented. Two-year posttransplantation overall survival (OS) for patients with primary refractory AML, patients with high-risk AML according to cytogenetic and molecular risk, and for patients with relapsed AML, were 59% (95% CI, 45% À 73%), 67% (95% CI, 45 À 88%) and 37% (95% CI, 19 À 54%), P ¼ 0.036, respectively, (Figure 1a) . Twoyear post-transplantation event-free survival (EFS) for the same three groups were 56% (95% CI, 42 À 71%), 55% (95% CI, 32 À 78%), and 37% (95% CI, 19 À 54%), P ¼ .067, respectively, (Figure 1b) . Primary refractory, high-risk and relapsed AML and other risk factors such as age, number of high-dose cytosine arabinoside-based chemotherapies, cytogenetic subgroups, FLT3 mutational status, bone marrow blasts prior to allogeneic HCT, and donor type were analyzed in a univariate fashion for the endpoints OS and EFS, with only AML status revealing a significant impact for OS at 2 years (Supplementary Table 2 ). Relapse incidence for patients with primary refractory AML, high-risk AML and relapsed AML were 4% (95% CI, 0 À 10%), 6% (95% CI, 0 À 16%) and 17% (95% CI, 3 À 30%), respectively, at day þ 100 and 26% (95% CI, 13% À 39%), 34% (95% CI, 11% À 57%) and 37% (95% CI, 19% À 54%), respectively, 2 years post transplantation ( Figures  1c and d) . Nonrelapse mortality (NRM) for patients with primary refractory AML, high-risk AML and relapsed AML were 11% (95% CI, 2% À 20%), 6% (95% CI, 0 À 16%) and 13% (95% CI, 1 À 26%), respectively, at day þ 100 and 17% (95% CI, 6 À 28%), 11% (95% CI, 0 À 26%) and 27% (95% CI, 10 À 43%), respectively, 2 years post transplantation (Figures 1e and f) . Reasons for NRM at 2 years after allogeneic HCT were infectious complications (n ¼ 12), aGvHD (n ¼ 5), cGvHD (n ¼ 2), and unknown in one patient who was lost to follow-up. Patients who underwent allogeneic HCT after initial diagnosis as part of first-line therapy were stratified according to FLT3-wildtype and intermediate-risk cytogenetics (n ¼ 10), FLT3-ITD-positive and intermediate-risk cytogenetics (n ¼ 8), and high-risk cytogenetics (n ¼ 40). Two-year OS for patients with FLT3-wildtype AML and intermediate-risk cytogenetics were 71% (95% CI, 48 À 95%) compared with 59% (95% CI, 42 À 76%) in patients with high-risk cytogenetics and 33% (95% CI, 3 À 64%; P ¼ 0.248) in patients with FLT3-ITD mutations and intermediaterisk cytogenetics (Figure 1g ). As shown in Figure 1h , similar trends could be observed for EFS in the aforementioned subsets.
For patients with primary refractory AML, high-risk genetics or relapsed disease in these AML categories, allogeneic HCT is the most potent antileukemic therapeutic approach, but even in younger patients o40% proceed to allogeneic HCT. 14 Potential reasons are: ineffectiveness of induction or salvage chemotherapies (including their cumulative toxicities), preexisting comorbidities and unavailability of matched donors. 13, 15 Our concept includes early allogeneic HCT during chemotherapyinduced aplasia even before a CR was established. We could confirm the promising data for AML patients who underwent allogeneic HCT during chemotherapy-induced aplasia, as reported by our group in 2006 for patients with newly diagnosed high-risk AML.
2 Importantly, it is worth considering that in the current analysis, not only newly diagnosed high-risk AML patients, but all consecutive patients, that is, also with relapsed AML with onethird being older than 60 years or having X20% bone marrow blasts prior to allogeneic HCT were included. The median time of 36 days from diagnosis to allogeneic HCT reported in this study is the shortest interval reported so far in the literature. However, it must be taken into account that this analysis is restricted to patients for whom a donor was available and does not represent an intent-to-treat analysis. Furthermore, a high bone marrow blast count prior to allogeneic HCT did not account for inferior OS or EFS, which was similar to the findings in the study published by Schmid et al. 7 In summary, a considerable proportion of patients with high-risk, refractory and/or relapsed AML were found to benefit from allogeneic HCT during aplasia, thus sparing additional chemotherapy and toxicities. With an increasing pool of available unrelated donors and more efficient algorithms of HLA-typing and donor search, prospective, multicentric trials for well-defined patient populations are needed to confirm these results.
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